Table_1_Synthetic Abortive HIV-1 RNAs Induce Potent Antiviral Immunity.docx
Strong innate and adaptive immune responses are paramount in combating viral infections. Dendritic cells (DCs) detect viral infections via cytosolic RIG-I like receptors (RLRs) RIG-I and MDA5 leading to MAVS-induced immunity. The DEAD-box RNA helicase DDX3 senses abortive human immunodeficiency virus 1 (HIV-1) transcripts and induces MAVS-dependent type I interferon (IFN) responses, suggesting that abortive HIV-1 RNA transcripts induce antiviral immunity. Little is known about the induction of antiviral immunity by DDX3-ligand abortive HIV-1 RNA. Here we synthesized a 58 nucleotide-long capped RNA (HIV-1 Cap-RNA58) that mimics abortive HIV-1 RNA transcripts. HIV-1 Cap-RNA58 induced potent type I IFN responses in monocyte-derived DCs, monocytes, macrophages and primary CD1c+ DCs. Compared with RLR agonist poly-I:C, HIV-1 Cap-RNA58 induced comparable levels of type I IFN responses, identifying HIV-1 Cap-RNA58 as a potent trigger of antiviral immunity. In monocyte-derived DCs, HIV-1 Cap-RNA58 activated the transcription factors IRF3 and NF-κB. Moreover, HIV-1 Cap-RNA58 induced DC maturation and the expression of pro-inflammatory cytokines. HIV-1 Cap-RNA58-stimulated DCs induced proliferation of CD4+ and CD8+ T cells and differentiated naïve T helper (TH) cells toward a TH2 phenotype. Importantly, treatment of DCs with HIV-1 Cap-RNA58 resulted in an efficient antiviral innate immune response that reduced ongoing HIV-1 replication in DCs. Our data strongly suggest that HIV-1 Cap-RNA58 induces potent innate and adaptive immune responses, making it an interesting addition in vaccine design strategies.
History
References
- https://doi.org//10.1016/S0966-842X(00)01830-8
- https://doi.org//10.1016/j.immuni.2008.05.016
- https://doi.org//10.1038/ni1162
- https://doi.org//10.1073/pnas.1108945108
- https://doi.org//10.1016/j.immuni.2011.05.003
- https://doi.org//10.1002/iub.1625
- https://doi.org//10.1038/nature04734
- https://doi.org//10.1128/JVI.01305-07
- https://doi.org//10.4049/jimmunol.1602121
- https://doi.org//10.1126/science.1132998
- https://doi.org//10.1126/science.1132505
- https://doi.org//10.1038/ni1243
- https://doi.org//10.1016/j.cell.2005.08.012
- https://doi.org//10.1073/pnas.81.21.6733
- https://doi.org//10.1016/j.coviro.2011.10.008
- https://doi.org//10.1038/nature12542
- https://doi.org//10.1038/nature12653
- https://doi.org//10.1038/ni.2229
- https://doi.org//10.1038/sigtrans.2017.23
- https://doi.org//10.1189/jlb.0112045
- https://doi.org//10.1182/blood-2005-06-2416
- https://doi.org//10.1128/MCB.15.10.5258
- https://doi.org//10.1038/sj.onc.1209943
- https://doi.org//10.1038/emboj.2008.126
- https://doi.org//10.1038/emboj.2008.143
- https://doi.org//10.1128/MCB.01603-12
- https://doi.org//10.1038/ni.3647
- https://doi.org//10.1371/journal.ppat.1000986
- https://doi.org//10.1128/JVI.01517-07
- https://doi.org//10.1038/emboj.2012.220
- https://doi.org//10.1093/nar/gkt306
- https://doi.org//10.1002/wrna.1165
- https://doi.org//10.1038/330489a0
- https://doi.org//10.1038/ni.1858
- https://doi.org//10.1016/j.cytogfr.2018.03.001
- https://doi.org//10.1016/j.chom.2014.06.008
- https://doi.org//10.1172/JCI34721
- https://doi.org//10.1182/blood.V97.9.2798
- https://doi.org//10.1093/toxsci/kfm178
- https://doi.org//10.1016/j.bbagrm.2010.05.004
- https://doi.org//10.1002/eji.200940203
- https://doi.org//10.1084/jem.20080091
- https://doi.org//10.18632/oncotarget.16593
- https://doi.org//10.1128/MCB.00285-18
- https://doi.org//10.1038/ncomms6074
- https://doi.org//10.1146/annurev-immunol-031210-101400
- https://doi.org//10.1016/j.immuni.2006.12.006
- https://doi.org//10.1084/jem.20111941
- https://doi.org//10.1038/nm.3054
- https://doi.org//10.1016/j.immuni.2013.08.031
- https://doi.org//10.1186/s12977-018-0437-y
- https://doi.org//10.1111/imr.12079
- https://doi.org//10.1038/nm1511
- https://doi.org//10.1016/j.jviromet.2016.12.017
- https://doi.org//10.1128/JVI.78.17.9105-9114.2004
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity